Recce Pharmaceuticals and Murdoch Children’s Research Institute Extend Collaborative Partnership
Friday, March 01, 2024
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has announced the ongoing progress of its Anti-Infective Research (AIR) Unit at the Murdoch Children’s Research Institute (MCRI), aimed at enhancing its preclinical programs and exploring new indications for future clinical trials.
Established in 2023, Recce's dedicated AIR Unit, led by Dr. Sohinee Sarkar, operates within MCRI's advanced research facilities. This collaboration underscores a joint commitment to pioneering innovation in anti-infective therapeutics.
The partnership has yielded significant strides in ongoing preclinical investigations of RECCE® 327, Recce's lead candidate, targeting various life-threatening infectious pathogens. These include Escherichia coli, associated with urinary tract infections and potentially lethal urosepsis, as well as Mycobacterium abscessus, Streptococcus pneumoniae, and Neisseria gonorrhoeae – the latter being a priority pathogen on the World Health Organization's list.
Professor Andrew Steer, MCRI's Theme Director of Infection, Immunity, and Global Health, emphasized the pressing need for collaborative efforts in combating antibiotic resistance. He hailed the partnership as pivotal in advancing antibiotic discovery and bolstering Australian leadership in this crucial domain.
The synergy between Recce's AIR Unit and MCRI epitomizes the potency of collaborative research in driving medical innovation. Their shared objective of advancing anti-infective research underscores a dedication to enhancing patient outcomes and tackling global health challenges head-on.
Recce Pharmaceuticals, affirmed the alignment of their ongoing work with MCRI's mission to combat antimicrobial resistance through innovative research. He expressed confidence in the collaborative potential between the two entities, foreseeing groundbreaking discoveries poised to revolutionize infectious disease treatment.
Source: globenewswire.com
